AVLN
Avalyn Pharma Inc.
$28.67
+2.17%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Insider Activity3B / 0S
Insider Net $$20.0M
SEC Reports9
Press Releases2
Recent Activity
Jun 3, 2026
SEC
Avalyn Pharma reported Q1 2026 results showing a net loss of $26.9M, wider than the $17.5M loss in Q1 2025, driven by in
8-K — Impact 4/10
Jun 3, 2026
earnings
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="center">On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulm
May 5, 2026
Press
Avalyn Pharma announced two presentations at the ATS 2026 conference, including a usability study of its AP01 nebulizer
Impact 2/10
May 5, 2026
SEC
Two insiders (Director Jill Carroll and 10% owner SR ONE CAPITAL) each purchased $5M of AVLN stock on May 1, 2026, at $1
CLUSTER — Impact 7/10
May 1, 2026
SEC
Two insiders (Director Jill Carroll and 10% owner SR One Capital Management) each purchased $5M of AVLN stock at $18/sha
CLUSTER — Impact 7/10
May 1, 2026
Insider
FMR LLC sold 377,948 shares
10%+ Owner @ $0.00 ($0.00)
May 1, 2026
Insider
FMR LLC sold 225,843 shares
10%+ Owner @ $0.00 ($0.00)
May 1, 2026
Insider
FMR LLC sold 872,868 shares
10%+ Owner @ $0.00 ($0.00)
Price Targets
$59.00
+105.8% upside
Strong Buy
Current $28.67
Low $51.00
Median $52.50
High $80.00
4 analysts
$51.00
$80.00
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Evercore ISI Group | INITIATE | Outperform |
| May 26, 2026 | Guggenheim | INITIATE | Buy |
| May 26, 2026 | Morgan Stanley | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.56 | $-0.65 — $-0.48 | 2 | |
| Next Q | $-0.58 | $-0.68 — $-0.49 | 2 | |
| Current FY | $-1.94 | $-1.94 — $-1.94 | 1 | |
| Next FY | $-1.90 | $-1.90 — $-1.90 | 2% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
Avalyn Pharma reported Q1 2026 results showing a net loss of $26.9M, wider than the $17.5M loss in Q1 2025, driven by in
Jun 3, 2026
NEUTRAL
Press
2/10
Avalyn Pharma announced two presentations at the ATS 2026 conference, including a usability study of its AP01 nebulizer
May 5, 2026
BULLISH
CLUSTER
7/10
Two insiders (Director Jill Carroll and 10% owner SR ONE CAPITAL) each purchased $5M of AVLN stock on May 1, 2026, at $1
May 5, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | FMR LLC | C | $0.00 |
| May 1, 2026 | FMR LLC | C | $0.00 |
| May 1, 2026 | FMR LLC | C | $0.00 |
| May 1, 2026 | FMR LLC | C | $0.00 |
| May 1, 2026 | FMR LLC | C | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
14 unique insiders with 3 transactions. Net insider value: $20.0M ($20.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 377,948 | $0.00 | $0.00 |
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 225,843 | $0.00 | $0.00 |
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 872,868 | $0.00 | $0.00 |
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 80,291 | $0.00 | $0.00 |
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 727,585 | $0.00 | $0.00 |
| May 1, 2026 | FMR LLC | 10%+ Owner | C | 727,585 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | BUY | 555,555 | $18.00 | $10.0M |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 3,327,734 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 18,000,000 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 1,986,369 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 12,558,081 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 25,899,284 | $0.00 | $0.00 |
| May 1, 2026 | Novo Holdings A/S | 10%+ Owner | C | 5,587,603 | $0.00 | $0.00 |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | 1,275,486 | $0.00 | $0.00 |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | 20,482,289 | $0.00 | $0.00 |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | 4,060,259 | $0.00 | $0.00 |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 1,419,298 | $0.00 | $0.00 |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | BUY | 277,778 | $18.00 | $5.0M |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 27,309,719 | $0.00 | $0.00 |
| May 1, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 9,418,561 | $0.00 | $0.00 |
| May 1, 2026 | Carroll Jill | Director | C | 1,419,298 | $0.00 | $0.00 |
| May 1, 2026 | Carroll Jill | Director | BUY | 277,778 | $18.00 | $5.0M |
| May 1, 2026 | Carroll Jill | Director | C | 27,309,719 | $0.00 | $0.00 |
| May 1, 2026 | Carroll Jill | Director | C | 9,418,561 | $0.00 | $0.00 |
| Apr 30, 2026 | Lavelle Erin | Director | A | 26,978 | $0.00 | $0.00 |
| Apr 30, 2026 | Carlson Douglas R | Chief Financial Officer | A | 211,975 | $0.00 | $0.00 |
| Apr 29, 2026 | Lazarus Howard | Chief Medical Officer | A | 211,975 | $0.00 | $0.00 |
| Apr 29, 2026 | Baranowski Lyn | Chief Executive Officer | A | 501,033 | $0.00 | $0.00 |
| Apr 29, 2026 | Haviland Kate | Director | A | 26,978 | $0.00 | $0.00 |
| Apr 29, 2026 | Rhodes Melissa | Chief Operating Officer | A | 211,975 | $0.00 | $0.00 |
| Apr 29, 2026 | Turner Heather D | Director | A | 26,978 | $0.00 | $0.00 |
| Apr 29, 2026 | Congleton Jon | Director | A | 26,978 | $0.00 | $0.00 |
| Apr 29, 2026 | Golden Adam H. | General Counsel | A | 254,891 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 4.6/10.
NEUTRAL
8-K
4/10
Avalyn Pharma reported Q1 2026 results showing a net loss of $26.9M, wider than the $17.5M loss in Q
Jun 3, 2026
BULLISH
CLUSTER
7/10
Two insiders (Director Jill Carroll and 10% owner SR ONE CAPITAL) each purchased $5M of AVLN stock o
May 5, 2026
BULLISH
CLUSTER
7/10
Two insiders (Director Jill Carroll and 10% owner SR One Capital Management) each purchased $5M of A
May 1, 2026
NEUTRAL
424B4
6/10
Avalyn Pharma priced its IPO of 16,666,667 shares at $18.00 per share, raising approximately $300 mi
Apr 30, 2026
NEUTRAL
3
3/10
Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing ownership of
Apr 30, 2026
NEUTRAL
3
2/10
FMR LLC filed a Form 3 initial statement of beneficial ownership for Avalyn Pharma Inc. (AVLN), disc
Apr 30, 2026
NEUTRAL
3
2/10
Heather Turner filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing 64,
Apr 29, 2026
NEUTRAL
S-1/A
5/10
Avalyn Pharma filed Amendment No. 2 to its S-1 registration statement for an IPO of 16,666,667 share
Apr 29, 2026
NEUTRAL
S-1/A
5/10
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled formulations of appro
Apr 23, 2026
Analyst Price Targets
$59.00 mean target
+105.8% upside
Strong Buy (1.25)
$51.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $28.67 |
| Target Low | $51.00 |
| Target Mean | $59.00 |
| Target Median | $52.50 |
| Target High | $80.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.56 | $-0.65 | $-0.48 | — | — | — | $0.0B | — | 2 |
| Next Q 2026-09-30 |
$-0.58 | $-0.68 | $-0.49 | — | — | — | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-1.94 | $-1.94 | $-1.94 | — | — | — | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$-1.90 | $-1.90 | $-1.90 | 2.1% | — | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.565 | |
| 7d ago | $0.000 | -0.565 |
| 30d ago | $0.000 | -0.565 |
| 60d ago | $0.000 | -0.565 |
| 90d ago | $0.000 | -0.565 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Evercore ISI Group | INITIATE | — | Outperform |
| May 26, 2026 | Guggenheim | INITIATE | — | Buy |
| May 26, 2026 | Morgan Stanley | INITIATE | — | Overweight |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
earnings
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="center">On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly prese
May 5, 2026
fda
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
<p align="left">BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering in
May 5, 2026
short_interest
FTD: AVLN — 55,823 shares ($1.6M) failed to deliver
Settlement: 20260505, Price: $29.07, FTD Value: $1,622,774.61, AVALYN PHARMA INC COM
May 4, 2026
short_interest
FTD: AVLN — 25,890 shares ($0.8M) failed to deliver
Settlement: 20260504, Price: $29.84, FTD Value: $772,557.6, AVALYN PHARMA INC COM
May 1, 2026
short_interest
FTD: AVLN — 39,278 shares ($1.2M) failed to deliver
Settlement: 20260501, Price: $29.49, FTD Value: $1,158,308.22, AVALYN PHARMA INC COM
Apr 30, 2026
offering
Avalyn Announces Pricing of Upsized Initial Public Offering
<p align="left">BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company